Figs Inc vs Synopsys, Inc. — how do they compare? Figs Inc trades at $14.26 (market cap $2.39B), while Synopsys, Inc. trades at $410 (market cap $78.83B). The key difference: Synopsys, Inc. is far larger — about 33× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| FIGS | SNPS | |
|---|---|---|
Market Cap | $2.39B | $78.83B |
Sector | Consumer Cyclical | Technology |
52-Week High | $17.12 | $625.80 |
52-Week Low | $6.57 | $372.33 |
Enterprise Value | $2.15B | $87.19B |
Signals from Pluang's Aura AI — not financial advice
FIGS stock surged 26.87% to $14.26, supported by strong Q2 2026 earnings that beat estimates with $0.11 EPS and 29% revenue growth. The technical outlook is bullish with moving averages aligned positively, while fundamentals show improving profitability with a net income margin of 8.72% and robust gross margins near 69%. Recent news highlights institutional buying and raised full-year guidance, reflecting strong operational momentum.
The outlook remains positive given consistent earnings beats and upward revenue revisions, though the stock's high P/E of 43.21 suggests premium valuation risks. Key investor risks include cost pressures from tariffs and freight, alongside competitive threats in the healthcare apparel space. Analyst consensus is bullish with a $19.50 price target, indicating potential upside from current levels.
Synopsys (SNPS) trades at $415.99, up 2.47% with strong technical momentum near resistance at $419. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.35 vs. $3.15 expected) and revenue growth to $7.05B in 2025. Recent developments include strategic AI partnerships with AMD and Microsoft, positioning the company at the forefront of chip design innovation.
Outlook remains positive with analyst consensus target of $559.50 suggesting 34% upside, though high P/E of 95.19 and aggressive cash flow investments in 2025-2026 present valuation and execution risks. The stock's bullish technical setup and strong institutional support outweigh near-term concerns for long-term investors.
Trailing returns across standard periods
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →